Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Enhancing Cancer Treatments through Fluorescence-Guided Surgery
share announcement

Enhancing Cancer Treatments through Fluorescence-Guided Surgery

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1753

Special Issue Editors

Dr. Ibrahim Khot

E-Mail Website
Guest Editor
School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK
Interests: cancer disease modelling; colorectal cancer; gut microbiome; healthcare theranostic platforms; photodynamic therapy; fluorescence-guided surgery; cancer-targeting nanomedicines
Dr. Yazan Sulaiman Khaled

E-Mail Website
Guest Editor
Leeds Institute of Medical Research, St James’s University Hospital, Leeds LS9 7TF, UK
Interests: pancreatic cancer modelling; surgical technology; fluorescence-guided surgery; targeted nanomedicine; photodynamic and photothermal therapy

Special Issue Information

Dear Colleagues,

Fluorescent-guided surgery (FGS) is a promising strategy, applied by surgeons for complete cancer resections with reduced damage to surrounding healthy tissue. FGS involves the use of photosensitive agents, aiding surgeons with real-time intraoperative fluorescent visualisations of cancers. It is successfully applied to delineate between cancerous and healthy tissues. FGS reduces tumour burden more efficiently and reduces the rate of tumour recurrences. In recent years, there has been an ongoing effort to develop the next generation of photosensitive agents that aim to address the limitations of current clinically used photosensitive agents. These studies have sought to exploit tumour physiologies and biomarkers, through cancer-targeting nanotechnologies, improving the uptake of agents; with deep NIR agents improving visual performance and the increase in FGS-specific sensitivity and specificity.

I am pleased to invite you to submit a manuscript relating to your interests in FGS. I welcome primary research articles, literature reviews and timely short communications that can impact the current state of FGS research. In particular, we welcome manuscripts focusing on the development of new fluorescent agents, payload delivery platforms, multimodal agents that fluoresce and exert tumour toxicity and any exciting advances in clinical applications.

I look forward to receiving your contributions.

Dr. Ibrahim Khot
Dr. Yazan Sulaiman Khaled
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fluorescence-guided resection
  • fluorescent imaging
  • cancer surgery
  • tumour targeting
  • intraoperative staging
  • oncological fluorescence
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1417 KiB  
Article
MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
by Kathryn M. Muilenburg, Evie G. Ehrhorn, Madeline T. Olson, Carly C. Isder, Kelsey A. Klute, Geoffrey A. Talmon, Mark A. Carlson, Quan P. Ly and Aaron M. Mohs
Cancers 2024, 16(20), 3439; https://doi.org/10.3390/cancers16203439 - 10 Oct 2024
Viewed by 830
Abstract
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Currently, surgical resection is the only potentially curative treatment. Unfortunately, less than 20% of PDAC patients are eligible for surgical resection at diagnosis. In the past few decades, neoadjuvant chemotherapy treatment (NCT) has [...] Read more.
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Currently, surgical resection is the only potentially curative treatment. Unfortunately, less than 20% of PDAC patients are eligible for surgical resection at diagnosis. In the past few decades, neoadjuvant chemotherapy treatment (NCT) has been investigated as a way to downstage PDAC tumors for surgical resection. Fluorescence-guided surgery (FGS) is a technique that can aid in increasing complete resection rates by enhancing the tumor through passive or active targeting of a contrast agent. In active targeting, a probe (e.g., antibody) binds a protein differentially upregulated in the tumor compared to normal tissue. Mucin 16 (MUC16), a transmembrane glycoprotein, has recently been explored as an FGS target in preclinical tumor models. However, the impact of chemotherapy on MUC16 expression is unknown. Methods: To investigate this issue, immunohistochemistry was performed on PDAC patient samples. Results: We found that MUC16 expression was retained after NCT in patient samples (mean expression = 5.7) with minimal change in expression between the matched diagnostic (mean expression = 3.66) and PDAC NCT patient samples (mean expression = 4.5). Conclusions: This study suggests that MUC16 is a promising target for FGS and other targeted therapies in PDAC patients treated with NCT. Full article
(This article belongs to the Special Issue Enhancing Cancer Treatments through Fluorescence-Guided Surgery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1380 KiB  
Review
Intra-Operative Tumour Detection and Staging in Pancreatic Cancer Surgery: An Integrative Review of Current Standards and Future Directions
by Ahmed Kotb, Zaynab Hafeji, Fadel Jesry, Nicole Lintern, Samir Pathak, Andrew M. Smith, Kishan R. D. Lutchman, Daniel M. de Bruin, Rob Hurks, Michal Heger and Yazan S. Khaled
Cancers 2024, 16(22), 3803; https://doi.org/10.3390/cancers16223803 - 12 Nov 2024
Viewed by 644
Abstract
Background: Surgical resection for pancreatic ductal adenocarcinoma (PDAC) entails the excision of the primary tumour and regional lymphadenectomy. This traditional strategy is challenged by the high rate of early recurrence, suggesting inadequate disease staging. Novel methods of intra-operative staging are needed to allow [...] Read more.
Background: Surgical resection for pancreatic ductal adenocarcinoma (PDAC) entails the excision of the primary tumour and regional lymphadenectomy. This traditional strategy is challenged by the high rate of early recurrence, suggesting inadequate disease staging. Novel methods of intra-operative staging are needed to allow surgical resection to be tailored to the disease’s biology. Methods: A search of published articles on the PubMed and Embase databases was performed using the terms ‘pancreas’ OR ‘pancreatic’ AND ‘intra-operative staging/detection’ OR ‘guided surgery’. Articles published between January 2000 and June 2023 were included. Technologies that offered intra-operative staging and tailored treatment were curated and summarised in the following integrative review. Results: lymph node (LN) mapping and radioimmunoguided surgery have shown promising results but lacked practicality to facilitate real-time intra-operative staging for PDAC. Fluorescence-guided surgery (FGS) offers high contrast and sensitivity, enabling the identification of cancerous tissue and positive LNs with improved precision following intravenous administration of a fluorescent agent. The unique properties of optical coherence tomography and ultrasound elastography lend themselves to be platforms for virtual biopsy intra-operatively. Conclusions: Accurate intra-operative staging of PDAC, localisation of metastatic LNs, and identification of extra-pancreatic disease remain clinically unmet needs under current detection methods and staging standards. Tumour-specific FGS combined with other diagnostic and therapeutic modalities could improve tumour detection and staging in patients with PDAC. Full article
(This article belongs to the Special Issue Enhancing Cancer Treatments through Fluorescence-Guided Surgery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop